[1]
Elinav, E.; Garrett, W.S.; Trinchieri, G.; Wargo, J. The cancer microbiome. Nat. Rev. Cancer, 2019, 19, 371-376.
[2]
Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M.; Vaysse, T.; Marthey, L.; Eggermont, A.; Asvatourian, V.; Lanoy, E.; Mateus, C.; Robert, C.; Carbonnel, F. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol., 2017, 28, 1368-1379.
[3]
Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.A.; Vicente, D.; Hoffman, K.; Wei, S.C. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.
[4]
Matson, V.; Fessler, J.; Bao, R.; Chongsuwat, T.; Zha, Y.; Alegre, M-L.; Luke, J.J.; Gajewski, T.F. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science, 2018, 359, 104-108.
[5]
Honda, K.; Littman, D.R. The microbiota in adaptive immune homeostasis and disease. Nature, 2016, 535, 75-84.
[6]
Spiljar, M.; Merkler, D.; Trajkovski, M. The immune system bridges the gut microbiota with systemic energy homeostasis: Focus on TLRs, mucosal barrier, and SCFAs. Front. Immunol., 2017, 8, 1353.
[7]
Zhang, H.; Sun, L. When human cells meet bacteria: Precision medicine for cancers using the microbiota. Am. J. Cancer Res., 2018, 8, 1157-1175.
[8]
Gopalakrishnan, V.; Helmink, B.A.; Spencer, C.N.; Reuben, A.; Wargo, J.A. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell, 2018, 33, 570-580.
